Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Davis Young

Physician Assistant Owego, NY Physician Assistant

NPI 1962912782 CMS profile 10557085

1246 State Route 38, Owego, NY 13827

Open in the dashboard

General payments

$4,812

216 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Davis Young of Owego, NY is reported in the CMS Open Payments database as having received $4,812 across 216 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $658 24
2024 General $1,148 50
2023 General $869 38
2022 General $1,121 59
2021 General $1,017 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Davis Young
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Davis Young were reported at $658. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Davis Young Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,017 $132 $37–$438 $132
2022 $1,121 $155 $48–$522 $149
2023 $869 $167 $52–$557 $160
2024 $1,148 $178 $55–$600 $164
2025 $658 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,669 60 payments
  2. AbbVie, Inc. $1,077 45 payments
  3. Novo Nordisk Inc $896 46 payments
  4. Pfizer Inc. $249 13 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $151 8 payments
  6. Exact Sciences Corporation $137 6 payments
  7. Janssen Pharmaceuticals, Inc $115 7 payments
  8. Lilly USA, LLC $110 7 payments
  9. E.R. Squibb & Sons, L.L.C. $107 7 payments
  10. Phathom Pharmaceuticals, Inc. $85 6 payments
  11. Other $215 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,812 216 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $1,005 40 payments
  2. UBRELVY $882 34 payments
  3. RYBELSUS $817 38 payments
  4. AIRSUPRA $692 20 payments
  5. Ozempic $608 39 payments
  6. QULIPTA $555 23 payments
  7. BREZTRI $291 3 payments
  8. ELIQUIS $249 13 payments
  9. SPIRIVA RESPIMAT $193 10 payments
  10. NURTEC ODT $142 7 payments
  11. Other $1,335 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 130 drugs

Part D claims

6,651

Median for Physician Assistant: 241

Drug cost

$723,600

Median for Physician Assistant: $4,110

Branded share of claims

21.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 85 $107,074
Rybelsus Semaglutide Brand 33 $73,056
Jardiance Empagliflozin Brand 59 $72,303
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 82 $70,493
Ozempic Semaglutide Brand 26 $63,020
Mounjaro Tirzepatide Brand 36 $51,779
Farxiga Dapagliflozin Propanediol Brand 33 $51,629
Xarelto Rivaroxaban Brand 22 $35,012
Januvia Sitagliptin Phosphate Brand 15 $23,689
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 21 $16,922

The 10 drugs with the highest cost, of 130 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$30,941

Of which drugs: $5,928

Medicare patients

165

Average age 73

Services billed

727

80 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Diabetes 32%
Arthritis 30%
Ischemic heart disease 24%
Chronic kidney disease 20%
COPD 18%
Heart failure 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 12 12 $3,468
Vaccine for influenza for injection into muscle 90662 Office 20 20 $1,636

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $307
$307 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $200
$200 33 —
UBRELVY
  • AbbVie, Inc. $118
$118 — —
QULIPTA
  • AbbVie, Inc. $109
$109 — —
RYBELSUS
  • Novo Nordisk Inc $81
$81 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record